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ABSRACT 
Vaginal candidiasis (VC) is second to bacterial vaginitis, as the most common opportunistic mucosal infection that affects large 
numbers of otherwise healthy women of childbearing age. The incidence of VC is significantly modified by dressing patterns and 
aberrant health-care practices. Contemporary young women often shift their preference from skirt to trousers and leggingswhich 
also coincides with a rise in auto-medication and over-the-counter drugs phenomena in our communities. These could result in 
increased occurrence of vaginal candidiasis infection and antifungal drug resistance. This was a cross-sectional study conducted 
between March 2011 and August 2011 among150 female students(aged 17-29 years) of the University of Buea.Socio-demographics 
information, risk factors and clinical symptoms were gotten through a standard questionnaire. Vaginal swabs were collected from 
each participant and cultured on Sabouraud'sdextrose agar supplemented with chloramphenicol (SDA-CAF). Identification and 
antifungal susceptibility testing was performed following standard microbiological procedures. Of the 150 participants who 
submitted vaginal swabs, yeasts was isolated in 98 (65.3%). Of the 98 yeasts isolates, 73.5% were Candida species, mainly C. 
albicans (65.3%). Overhalf (64.7%) ofstudyparticipantshadapreferencefortrousers,however, this attitude was not significantly 
associated (p = 0.559) with candidiasis.Previous episodes of vaginal infection and treatment for candidiasis were significantly 
associated with VC (p = 0.004). Antifungal susceptibility results showed a high resistance to fluconazole (82.0%), nystatin (80.0%) 
and ketoconazole (72.0%), while clotrimazole (50.0%) was the most activeantifungal drug. There was a high prevalence of VC in 
this study population with previous vaginal infectionbeing important risk factor for reoccurrence. Clotrimazole was the drug of 
choice in the treatment of VC in this population.  
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PROFILS DE SENSIBILITE AUX ANTIFONGIQUES ET FACTEURS DE RISQUE DE CANDIDOSE VAGINALE 
CHEZ LES ETUDIANTES UNIVERSITAIRES AU SUD-OUEST DU CAMEROON 
TITRE COURANT:PROFILS DE SENSIBILITE AUX ANTIFONGIQUES ET FACTEURS DE RISQUE DE CANDIDOSE 
VAGINALE CHEZ LES ETUDIANTES UNIVERSITAIRES 
La candidose vaginale (CV) est la deuxième infection opportuniste de la muqueuse la plus fréquente (après la vaginite 
bactérienne) qui affecte un grand nombre de femmes en âge de procréer. L'incidence de la CV est affectée de façon significative 
par certaines habitudes vestimentaires et pratiques de soins de santé « aberrante »s. Chez les jeunes femmes contemporaines, les 
pantalons et leggings sont de plus en plus préférés aux jupes, ce qui coïncide aussi avec une augmentation du phénomène 
d'automédication dans nos communautés. Ces deux facteurs pourraient entraîner une augmentation de la prévalence de l'infection 
à Candida vaginale et la résistance aux antifongiques. La présente étude transversale a été menée entre Mars et Août 2011 portait 
sur 150 étudiantes âgées de 17 à 29 ans, à l'Université de Buea (Cameroun). Elle avait pour objectifs majeurs d’évaluer les profils de 
sensibilité aux antifongiques ainsi que les facteurs de risque de candidose vaginale chez les étudiantes universitaires. Les données 
sociodémographiques, informations sur les facteurs de risque et les symptômes cliniques ont été explores à l’aide d’un 
questionnaire semi-structuré. Des spécimens vaginaux ont été prélevés dans chaque participante et soumis à une culture sur le 
dextrose gélose de Sabouraud supplémenté par le chloramphénicol (SDA-CAF). Les tests d'identification et de sensibilité 
antifongique ont été réalisés suivant des procédures microbiologiques standard. Parmi les 150 participants qui ont soumis des 
prélèvements vaginaux, des levures ont été isolées de 98 personnes (65,3%). Sur les 98 levures isolées, 73,5% étaient des espèces de 
Candida, principalement C. albicans(65,3%). Plus de la moitié des participants (64.7%) ont exprimé des préférences pour les 
pantalons et autres styles vestimentaires émergents. Cependant, de telles attitudes n’ont pas paru statistiquement associées à 
l’occurrence des candidoses au sein de la population ciblée (p = 0.559). Des précédents épisodes d'infection vaginale et le 
traitement de la candidose reportés par les participantes étaient significativement associés à CV (p = 0,004). Les résultats de 
sensibilité antifongiques ont montré une grande résistance au Fluconazole (82,0%), Nystatine (80,0%) et Kétoconazole (72,0%), 
tandis que le Clotrimazole (50,0%) était le médicament antifongique le plus actif. Il y avait une forte prévalence de CV dans cette 
population d'étude avec infection vaginale précédente étant facteur de risque important pour la répétition. Le Clotrimazole s’est 
avéré comme étant le médicament de choix dans le traitement des CV dans cette population, malgré la forte résistance. 





Bacterialvaginitis, vaginal candidiasis and 
trichomoniasis are responsible for 90% of the cases of 
vaginal infections (1). Vaginal candidiasisissecond to 
bacterial vaginitis(2), as the most common 
opportunistic mucosal infection that affects large 
numbers of otherwise healthy women of childbearing 
age (3, 4). VC usually occurs when there is overgrowth 
of the fungus, Candida, present in the body as a normal 
commensal(5)whichis characterized by curd-like 
vaginal discharge and itches(6). Up to 75% of 
reproductive-age women are infected with VC at least 
once (6, 7) and about half of these women experience 
more than one recurrence, and 5%– 8% have multiple 
episodes each year(7). In addition to discomfort and 
the costs associated with medication and health care 
visits, several prospective studies have suggested that 
VC may increase a woman’s risk of contracting other 
sexually transmitted diseases such ashuman 
immunodeficiency virus(9). 
Although VC in pre-menarchal and post-menopausal 
women is rare, there are several endogenous and 
exogenousfactors that predispose menarchal women to 
acute VC; including several hormonal modulations 
associated with pregnancy, luteal phase of the 
menstrual cycle, oral contraceptive use, hormone 
replacement therapy and non-hormonal factors such as 
antibiotic use and uncontrolled diabetes mellitus(10).  
 
Dressing pattern such as tight clothing and synthetic 
underwear have been reported to increase the risk of 
candidiasis(10, 11)although other investigatorshave 
contrary reports(12, 13). In recent times, young women 
often shift their preference from skirt to 
trousers/leggings or tight under wears and this also 
coincides with a rise in auto-medication and over-the 
counter drugs phenomena in our communities. Access 
to over-the-counter medications allows women to self-
diagnose and treat vaginal symptoms (5). These and 
other possible risk behaviours could result in the 
increase prevalence of vaginal candidiasis and 
antifungal drug resistant.Consequently, the present 
study sought to investigate the prevalence of VC, 
determine the possible risk factors and antifungal 
sensitivity patternsamong female students of 
reproductive age at the University of Buea.Such data 
will provide important information in developing 
effective strategies for the prevention, control and 
possible treatment options for VC. 
 
MATERIAL AND METHODS 
Study design and population 
This cross-sectional study was conducted between 
March 2011 and August 2011. The study population 
comprised female students of child-bearing age (17-29 
years) enrolled in both postgraduate and 
undergraduate programs at the University of Buea, 
who gave their consent to participate in the study. 
Questionnaires were administered to obtain 
information on demographics, risk factors and medical 
history of VC. 
Sample  collectionSamples were collected as 
previously reported (15). Briefly, each participant was 
given a sterile swab stick and instructed to self-collectan 
early morning vaginal swab before bath by introducing 
the sterile swab into vaginal area and gently moving 
the swab by rotatingand allowing for some time to 
absorbed vaginal discharge. The samples were 
delivered within 2 hours to Life Science teaching 
laboratory of the University of Buea for analysis. 
Culture and Microscopy                                                           
Samples were inoculated on Sabouraud's dextrose 
agarsupplemented with chloramphenicol (SDA-CAF) 
(Plasmatec Laboratory Products LTD, UK). The plates 
were incubated aerobically at 37oC for 24 – 48hours 
after which they were examined for raised, cream-
coloured, opaque, yeast smelling colonies. 
Morphologically distinct colonies from each culture 
were sub-culturedand stored on SDA slant for 
subsequent identification.Vaginal swabs were rolled 
onto slides, air dried and Gram stained following 
standard microbiological procedures. The slides were 
viewed with light microscope at 100X for yeast 
morphology. Wet mount preparations were prepared 
by placing the swab stick into 0.5ml sterile normal 
saline and mixed vigorously. A drop of the suspension 
was then placed on a clean labelled slide, covered with 
a cover slip, and carefully examined under a 
microscope using the 40X objective to observe yeast 
morphology.  
Identification and antifungal susceptibility testing 
Positive cultures were further tested for germ tube 
formation (evidence for C. albicans). Discrete colonies 
were inoculated in bovine serum and incubated at 35-
37oC for 2-3hours. The serum preparations were then 
transferred on slides and viewed under the microscope 
(10X and 40X objectives) for the presence of 
germinating blastospores or germ tube formation. A 
complete identification of yeast isolates was carried out 
usingAnalytical Profile Index for Candida (API Candida 
kit, BioMerieux SA) according to manufacturer’s 
instructions.Antifungal sensitivity testing was 
performed only on Candida species isolates, using the 
modified Kirby-Bauer disc diffusion method on SDA as 
previously reported(16). The antifungal discs [potency] 
used included nystatin [100 IU], fluconazole [100 µg], 
ketoconazole [10 µg] and clotrimazole [50 µg].  
The data was recorded and analysed using descriptive 
analysis and Chi-square on SPSS Version 11.0 statistical 
software at 0.05 significance level. Ethical clearance for 
the study was obtained from the Regional Delegation of 
Public Health for the Southwest region.  
RESULTS 
Study population description and clinical 
presentationOne hundred and fifty female students, 




study, with 68% being symptomaticand 32% 
asymptomatic cases. The reported clinical symptoms 
included vaginal itches (57.3%), abnormal vaginal 
discharge (31.3%) and burning pain 
sensations(14%).Over half (64%) of the participants 
accepted to have had previous episodes of VC and 
among them half (48/96), sought for medical attention 
and VC was diagnosed by laboratory findings while 
the remainder were self-diagnosed. Of those who were 
self-diagnosed, 23 (47.9%) reported to have taken auto-
medication. A total of 64.7% of the study participants 
acknowledged preference for trousers while 49.3% 
preferred tight under wares. Majority (70%) of the 
participants reported haverecently use antibiotics 
while 15.3% accepted have been on oral contraceptives. 
Prevalence of Candida species in the study 
population 
Microscopic examination of wet preparation showed 
presence of yeast cells in 48.7% (73/150) 
occurringmostly as single cells/bud (72.6%), while the 
rest (27.3%) presented as ovoid buds/pseudo-hyphae. 
A total of 85 of the samples (56.7%) were positive by 
Gram stained smears while 98 (65.3%) were identified 
by culture.Of the 98 positive cultures, 48% (47/98), 
25.5% (25/98) and 26.5% (26/98) showed profuse, 
moderate and scanty growth respectively on SDA. Half 
(50%) of the isolates produced germ tubes and hence 
were presumptively considered Candida species. Isolates 
were further identified with Analytical Profile Index 
for Candida species(API candida). Overall, based on 
germ tube identification test and the API candida test, 
73.5% (72/98) of the isolates were identified as Candida 
species while 26.5% (26/98) of the isolates were non-
candida species. The Candida species,includedC. 
albicans(42.7%),C. tropicalis (3.4%),C. glabrata(1.3%) and 
C. krusei (0.7). Other yeast species identified were 
Saccharomyces cerevisiae (12.7%) and Trichosporon species 
(4.7%).(Table 1). 
 
TABLE 1: PREVALENCE OF CANDIDA SPECIES AND OTHER YEAST SPECIES IN THE STUDY POPULATION 
Yeasts species Germ tube test API candida positive Total 
(%) 
Total prevalence (%) 
C. albicans 49 15 64 (42.7)  
Candida spp 
72 (73.5) C. tropicalis / 05 05 (3.4) 
C. glabrata / 02 02 (1.3) 
C. krusei / 01 01 (0.7) 
Saccharomyces cerevisiae / 19 19 (12.7) Other yeast 
26 (26.5) 
Trichosporon species / 07 07 (4.7) 
Total 49 49 98 (65.3) 
 
 
Antifungal susceptibility testingAntifungal 
susceptibility testing results was classified as 
susceptible, intermediateor resistant. Our results 
revealed that isolates were most susceptible to 
clotrimazole50.0% (25/50). On the other hand, none of 
the isolates were susceptible to fluconazole and 
nystatin, although some isolates showed intermediate 
to fluconazole (18.0%) and to and nystatin (20.0%). 
Resistance to fluconazole,nystatinand ketoconazole 
were (82%), (80%) and (72%) respectively (Figure 1). 
 





























Risk factors associated with vaginal candidiasis 
Although not significantly different, VC was higher 
among symptomatic (OR: 1.20, 95% confidence 
interval [CI]: 0.59-2.45) than non-symptomatic 
subjects, in participants who preferred tight (OR: 
1.37, 95% CI: 0.69-2.69) than loose under wears, and 
also among those who had preference for trousers 
(OR: 1.23, 95% CI: 0.61-2.47) than skirt outfit. 
Similarly, use of oral contraceptives (OR: 1.25, 95% 
CI: 0.48-3.28) and recent use of antibiotics (OR: 1.44, 
95% CI: 0.68-3.08) both increase the risk of vaginal 
candidiasis. Previous episodes of vaginal infection 
(OR: 2.79, 95% CI: 1.38-5.64) was significantly 
associated (p = 0.004) with vaginal candidiasis. On 
the other hand previous treatment for VC (OR: 0.36, 
95% CI: 0.18-0.72) was protective against VC. (Table 
2). 














Presence of clinical signs 
and symptoms 
Yes 102 (68.0) 68 (66.7) 34 (33.3) 1.20 [0.59-2.45] 0.617 
No 48 (32.0) 30 (62.5) 18 (37.5) 1 
Previous episodes of 
vaginal infection 
Yes 96 (64.0) 72 (75.0) 24 (25.0) 2.79 [1.38-5.64]* 0.004 
No 54 (36.0) 28 (51.9) 26 (48.1) 1 
Previously treated for 
vaginal candidiasis 
Yes 72 (48.0) 37 (51.3) 35 (48.3) 0.36 [0.18-0.72]* 0.004 
No 78 (52.0) 58 (74.4) 20 (25.6) 1 
Under wares Tight 74 (49.3) 51 (68.9) 23 (31.1) 1.37 [0.69-2.69] 0.363 
Loose 76 (50.7) 47 (61.8) 29 (38.2) 1 
Dressing outfit Trousers 97 (64.7) 65 (67.0) 32 (33.0) 1.23 [0.61-2.47] 0.559 
Skirts 53 (35.3) 33 (62.3) 20 (37.7) 1 
Douching Yes 79 (52.7) 48 (60.8) 31 (39.2) 0.65 [0.34-1.28] 0.216 
No 71 (47.3) 50 (70.4) 21 (29.6) 1 
Oral contraceptives Yes 23 (15.3) 16 (69.6) 07 (30.4) 1.25 [0.48-3.28] 0.644 
No 127 (84.7) 82 (64.6) 45 (35.4) 1 
Recent use of antibiotics Yes 105 (70.0) 78 (74.3) 27 (25.7) 1.44 [0.68-3.08] 0.342 





DISCUSSION                                      
This study investigated the prevalence of VC, 
antifungal resistance profiles and possible risk 
factors among female students in the University of 
Buea. The overall prevalence of yeast species was 
65.3%.However, the prevalence of Candida species in 
this study was 48% with C. albicans having the 
highest prevalence (42.7%) in conformity with prior 
studies(17, 4, 18).As previously demonstrated, C. 
albicansis the most predominant yeast species in the 
environment and hence occurs as a normal human 
vaginal flora. More so, its ability to form germ tube 
confers it survival abilities over other yeast 
species(19). 
Generally, laboratory diagnosis of VC in resource-
limited settings like ours is accomplished most often 
with less a sensitive microscopic examination of 
fresh and grams stained smears of vaginal 
specimens. In this study the prevalence of yeast by 
microscopic examination of wet preparation was 
48.7%, which increased to 56.7% by microscopy of 
gram stained smears. The prevalence further 




improves diagnosis of VC, this is not a common 
method of laboratory diagnosis in this setting and 
therefore, adequate characterisation of Candida 
albicans by microscopy remains challenging. 
Presumptive identification ofC. albicansisolates can 
be achieved with germ tubes test and in this study 
up to 50% of the culture positive isolates were 
identified. Commercial identification test provide 
more sensitive and specific method for 
differentiating non-albicansCandida species. Three 
non-albicans species were identified (C. tropicalis, C. 
glabrata, C. krusei) and the two other yeast species 
(Saccharomyces cerevisiae and Trichosporon species) 
with API candida test kit.Unlike many previous 
findings which predominantly isolated Candida 
species and considered to be the main cause of VC (4, 
18), our results revealed that S. cerevisiae and 
Trichosporon species could be responsible for causing 
VC since they were isolated from symptomatic 
subjects. In support of this findings, S. cerevisiae and 
rarely Trichosporon species(21)have also been isolated 
in vaginal infections and were assumed to be 
emerging pathogens isolated from fungal 
infections(22). 
We also evaluated the antifungal susceptibility 
patterns of the Candida isolates to commonly 
prescribed and readily available drugs in the 
locality. Fifty per cent of Candida specieswere 
susceptible, while 24% were intermediate to a 
member of the azole group (clotrimazole), used in 
the study. Clotrimazoleis one of the reserved 
antifungal not frequently prescribed in the 
treatment of VC in this setting. Few (14%) of the 
isolates were susceptible to ketoconazole and 
showedno susceptibility to fluconazole. VC is 
treated effectively with azole-based antifungal 
drugs(23), however, most of the isolates were 
found to be resistant to ketoconazole (76%) 
andfluconazole (82%). On the other hand, the high 
resistance observed in nystatin (80%), (a polyene) 
could be blamed to the excessive use of this drug in 
the locality as topical ointment or suppository as a 
result of its availability and low cost. 
As previously reported itching sensations, burning 
internal pain and cream white ‘cheesy’ discharge 
were the main reported symptoms with majority of 
the symptomatic participantshaving vaginal itches 
(57.3%)(20).Among those who reported previous 
vaginal infections, self-diagnosis (50%) and auto-
medication (47.9%)were common practices. This 
behaviour is prompted by the availability of over-
the-counter drugs. There was no statistically 
significant difference in the prevalence of yeast 
among symptomatic and asymptomatic subjects. A 
good number of women are infected with VC 
without any significant discomfortand this may be 
as results of the fact symptoms of VC, such as 
vaginal itches, abnormal vaginal discharge and 
burning vaginal pains are very nonspecific (8). 
Even though, not statisticallysignificant in this 
study, tight fitting garments, trousers and synthetic 
underwear have been previously reported to 
increase the risk of VC (12) by increase temperature 
and humidity of the vaginal and hence may 
provide a more favourable environment for the 
growth of the organisms.However, other 
investigators have contrary reports (13, 14). Our 
studyshowed that previous vaginal infection was 
significantly associated (p =0.004) with the 
occurrence of VC.In line with prior studies (8, 22, 
23, 24), recent use of antibioticsand oral 
contraceptives wereinsignificantly associated with 
VC. Nevertheless, antimicrobials tend todeplete the 
protective vaginal bacterial flora that normally 
keeps yeast in balance, hence the yeast overgrows 
and causes VC, meanwhile oral contraceptives are 
associated with increase oestrogen levels resulting 
in high glycogen in vaginal lining, a substrate on 
which C. albicans thrives (8, 23).Contrary to other 
studies douching (12)and previous treatment for 
VC were negatively correlated with the prevalence 
of VC but agrees with others reports(27)where no 
relationship existed between douching and VC. 
 
In conclusion, this study demonstrated a high 
prevalence of VC among the study participants 
with previous vaginal infection being an important 
predictor of VC reoccurrence.Candida albicans 
continue to be the predominant species while the 
best antifungal treatment option in this locality is 
clotrimazole. 
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